Shows
Hämatologie ShortcastsASH 2025 - AML im Umbruch?Live vom ASH 2025 in Orlando spricht Dr. Andreas Hausmann mit Prof. Dr. med. Thomas Schroeder vom Universitätsklinikum in Essen über die wichtigsten Entwicklungen im Bereich der myeloischen Neoplasien – mit besonderem Fokus auf AML, MDS und die allogene Blutstammzelltransplantation.Im Mittelpunkt stehen aktuelle ASH-Daten zur Next-Generation-FLT3-Inhibition mit Gilteritinib, inklusive neuer Post-hoc-Analysen zur Erhaltungstherapie nach allogener Transplantation und zur Bedeutung von MRD und Timing der Transplantation. Diskutiert wird, welche Patient:innen tatsächlich profitieren könnten – und ob Gilteritinib künftig eine Alternative zum bislang etablierten Sorafenib werden kann.Ein weiterer Schwerpunkt liegt auf Kombinationstherapien mit HMA u...
2025-12-1732 min
HemaSphere PodcastEHA/EBMT Survey on Grading and Management of ICAHT - Ep 3.7Join our host HemaSphere Scientific Editor Dr Charles de Bock as he chats with Dr Kai Rejeski, first author of this 2025 HemaSphere Top Cited –Clinical Award-winning paper. The conversation delves into the complexities of CAR-T therapy, particularly focusing on the associated toxicities and the need for a structured grading system. EHA/EBMT Survey on Grading and Management of ICAHT, is on our website and all major podcast platforms (Spotify, Apple Podcast, and more) and YouTube. Listen and enjoy casual, insightful discussions about #hematology research. You can find the referenced article, in full and open access, he...
2025-10-0140 min
Blood PodcastEarly prediction of follicular lymphoma patients with poor survival; immune hotspots in aplastic anemia; role of allo-transplant for Hodgkin lymphoma in the checkpoint inhibitor eraIn this week's episode we'll learn about how by combining PET response with circulating tumor DNA, or ctDNA, in newly treated patients with follicular lymphoma, investigators identify those patients likely to progress within 24 months of initial treatment, also known as POD24. After that: Immune hotspots in aplastic anemia. These newly identified hotspots potentially represent sites in the bone marrow where the active immune response takes place, driving the destruction of hematopoietic stem and progenitor cells. Finally, allogeneic transplantation for Hodgkin lymphoma in the checkpoint inhibitor era. In a large, retrospective study, patients with prior checkpoint inhibitor exposure had remarkable o...
2025-08-2119 min
HaemlineWar of the Cords: Optimising Graft-versus-Leukaemia in Double Cord Blood TransplantationIn double cord blood transplantation, one unit engrafts and the other is rejected—but the losing unit might be doing more than previously imagined. A 2025 Blood Advances study from the Eurocord–EBMT registry reveals how the immunological battle between cord units can be redirected against leukaemia, particularly when the patient and losing unit share the right HLA mismatches. In this episode, we unpack the elegant biology behind this unintended vaccine effect, explore the surprising lack of excess GVHD, and consider what these findings mean for unit selection in high-risk disease. Could the losing graft be the key to preventing rela...
2025-08-0415 min
VJHemOnc PodcastHighlights from EBMT 2025: preventing and managing GvHD, harnessing AI in transplant, & moreIn this week’s VJHemOnc podcast, we’ll be sharing highlights from the 51st Annual Meeting of the EBMT, with a focus on the prevention and management of graft-versus-host disease (GvHD) and infections associated with stem cell transplantation (SCT). You will also hear about the potential of artificial intelligence (AI) in hematology and transplantation.
Tune in as experts Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, and Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, provide insights into current treatment approaches for acute and chronic GvHD, discussing the advent of new therapies. Following this, you’ll hear a...
2025-04-1722 minVJHemOnc PodcastHighlights from EBMT 2025: preventing and managing GvHD, harnessing AI in transplant, & moreIn this week’s VJHemOnc podcast, we’ll be sharing highlights from the 51st Annual Meeting of the EBMT, with a focus on the prevention and management of graft-versus-host disease (GvHD) and infections associated with stem cell transplantation (SCT). You will also hear about the potential of artificial intelligence (AI) in hematology and transplantation.
Tune in as experts Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, and Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, provide insights into current treatment approaches for acute and chronic GvHD, discussing the advent of new therapies. Following this, you’ll hear a...
2025-04-1722 min
Weekly Neurology Deep Dive - A review of recent impactful publications in the field of NeurologyBone marrow transplantation for MS, ECTRIMS RecommendationAutologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT
2025-04-1213 min
RealTalk MSUnderstanding Gut Health and MS with Dr. Ashutosh MangalamWhen we talk about myelin damage, most of us typically think of the brain. After all, that myelin is located in your central nervous system. But the inflammation that causes myelin damage may be triggered by activity that's taking place well south of your central nervous system, in your gut microbiome, the colony of trillions of bacteria and microorganisms that live in your intestines. Dr. Ashutosh Mangalam joins me to help us understand what this gut-brain connection is all about, how that connection impacts MS, and what you can do to change the makeup of...
2025-02-0437 min
Transplant & Oncology ID: Literature Dives06: Adenovirus After Allo HCTThis study, published in Bone Marrow Transplantation, analyzes adenovirus (ADV) infections in children and adults after allogeneic hematopoietic cell transplantation (allo-HCT). Researchers examined 2529 patients from the EBMT database, identifying risk factors for mortality. Children demonstrated better short-term survival than adults, with different factors influencing mortality in each group. In children, pre-transplant factors like CMV serostatus and performance score were key, whereas in adults, factors directly related to ADV infection, such as the type of infection and time of onset, were more impactful. The study highlights the need for regular ADV screening in both children and adults post-allo-HCT.
...
2024-12-1607 min
EHA UnpluggedRegulatory Landscape for CAR T-cell TherapyJoin us for an interview with Professor Julio Delgado from the Hospital Clinic de Barcelona (Spain), the first academic centre to achieve the authorisation to treat patients with a CAR T therapy developed 100% by academia. Prof Delgado discusses the complexities of obtaining regulatory approval for CAR T-cell therapy, under the EU regulation for advanced therapy medicinal products (ATMPs). In this episode, Prof Delgado shares his own experience learning to navigate the EU regulatory expectations while working at the European Medicines Agency (EMA). He emphasizes the importance of scientists understanding these regulations and regulators understanding the sp...
2024-08-3011 minEHA UnpluggedPoint-of-care CAR T-cell ManufacturingJoin us for this podcast discussing the promises and challenges of academic and point-of-care CAR T-cell manufacturing with Dr Anna Sureda, president of EBMT (European Society for Blood and Marrow Transplantation). Dr Sureda provides her expert point of view on how CAR T-cells produced in academic centres may enhance patient access to CAR-T treatment, reducing costs and turnround times for production, and on the regulatory and quality issues linked to decentralized manufacturing of CAR T-cells. Discover the current European landscape for academic CAR-T production, the evidence and experiences accumulated so far, and th...
2024-08-2321 minEHA UnpluggedProcesses in CAR T-cell TherapyJoin us for an interview with Professor Julio Delgado from the Hospital Clinic de Barcelona (Spain) as he explains the intricate process of CAR T-cell therapy. In this episode, we cover the key steps involved in CAR T, such as patient identification, apheresis, manufacturing, cell infusion and managing post-infusion related toxicities. Prof Delgado offers expert insights on each component of this complex treatment and discusses possible improvements. He also highlights efforts to shorten vein-to-vein time and the importance of academic and non-profit manufacturing in reducing costs. This conversation offers a solid overview for clinicians and hematologists interested...
2024-08-1627 minEHA UnpluggedCAR T-cell Therapy for Children with ALLTune in to our podcast for an in-depth discussion on CAR T-cell therapy for acute lymphocytic leukemia (ALL) in children. In this episode, we feature Professor Concetta Quintarelli, a renowned expert in hematology from the Bambino Gesù Children Hospital in Rome.With host Isabel Olivera, they explore the advancements and challenges in treating ALL with CAR T-cells, the balance between treatment efficacy and safety, and the potential of combining CAR T-cells with other immunotherapies. The episode also delves into the complexities of the tumor microenvironment in ALL, antigen selection for targeted therapy, and the design of smarter CAR...
2024-08-0918 minEHA UnpluggedCAR T-cell Therapy in AML: State of the ArtTune in to our podcast for an in-depth discussion on immunotherapeutic strategies for Acute Myeloid Leukemia (AML). In this episode, we feature Dr Sarah Tettamanti, a senior scientist at the Fondazione Tettamanti Research Centre in Italy, who shares her expertise on CAR T-cell therapy for AML. With host Dr Sarah de Vlieger, they examine the progress and challenges in treating AML with CAR T-cells, the balance between treatment efficacy and safety, and the potential of combining CAR T-cells with other immunotherapies. The episode also covers the complexities of the tumor microenvironment in...
2024-08-0215 minEHA UnpluggedEthical Considerations in CAR T-cell TherapyWelcome to a thought-provoking episode of our podcast series, where we dive into the ethical and practical challenges of CAR T-cell therapy with Professor Marie José Kersten from Amsterdam University Medical Centers.In this episode, our host Dr Isabel Olivera engages in a deep dive with Professor Kersten on the intricacies of patient access to CAR T-cell therapy, the ethical considerations in patient selection, and the financial implications of this groundbreaking treatment.Discover the rigorous process of patient eligibility assessment in the Netherlands, the national CAR-T tumorboard's role, and the ongoing efforts t...
2024-07-2621 minEHA UnpluggedCAR T-cell Therapy - A Patient's PerspectiveJoin us for a conversation with Jonathan Clark, a patient advocate who has been in remission for over five years after receiving CAR T-cell therapy for Mantle Cell Lymphoma. Jonathan shares his journey from relapse to recovery, detailing the challenges and triumphs of this cutting-edge treatment from a patient’s perspective. With host Dr. Sarah de Vlieger, they discuss his motivation for sharing his story and the profound physical and psychological impacts of long-term remission. Jonathan also talks about managing long-term side effects like immunodeficiencies and how apparently small changes can significantly improve quality of li...
2024-07-1912 minBlood PodcastAcalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL; alternative donor transplantation for severe aplastic anemia; clonal relapse dynamics in AML following allogeneic HCTIn this week's episode we’ll discuss the safety and efficacy of acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL; learn more about alternative donor transplantation for severe aplastic anemia and discuss clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation.Featured Articles: Acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation
2024-07-1823 minEHA UnpluggedDevelopments in CAR T-cell TherapyJoin us for a captivating interview with our guest Professor Michael Hudecek from the Universitätsklinikum Würzburg in Germany as he offers his insights on the latest advancements in CAR T-cell therapy and gene-engineered immune cell therapies. Together with our host Dr. Isabel Olivera Martinez, they discuss the mounting real-world data on CAR T-cell treatments and how AI is helping analyze this data to design new strategies and extend CAR-T to new indications. Discover the strides being made to predict and manage treatment-related toxicities and to make CAR T-cell therapy more accessible and affordable, inc...
2024-07-1218 min
Medscape InDiscussion: MyelofibrosisRisk Stratification in Myelofibrosis: Which Model Should You Use?Join Drs Tania Jain and Pankit Vachhani as they discuss the nuance involved in the risk stratification of myelofibrosis and the latest research in prefibrotic myelofibrosis. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999593. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Primary Myelofibrosis: Risk Stratification by IPSS Identifies Patients With Poor Clinical Outcome https://pubmed.ncbi.nlm.nih.gov/23644853/ DIPSS Plus: A Refined Dynamic International Prognostic Scoring...
2024-07-0326 min
TMO EPM / Hemato H9J29 - Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMTDiscussão do artigo: "Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMT" de Sanz J Blood 2024
Apresentado por: Dra Luana Pompeu
Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dr. Gabriel Coquito, Dr. Pedro Arruda e Dr. Vinicius Molla.
2024-05-2722 minVJHemOnc PodcastHighlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiomeGraft-versus-host disease (GvHD) is a common complication following allogeneic stem cell transplantation (alloSCT), which is typically classified as acute or chronic. In this week’s VJHemOnc podcast, we’ll be sharing key highlights from the 50th Annual Meeting of the EBMT, drawing focus on the biology and treatment of GvHD.
Tune in as experts Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, Ernst Holler, MD, University Hospital Regensburg, Regensburg, Germany, and Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, provide insights into current and emerging treatment approaches for acute and chronic GvHD, discussing the adven...
2024-04-2622 minVJHemOnc PodcastHighlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiomeGraft-versus-host disease (GvHD) is a common complication following allogeneic stem cell transplantation (alloSCT), which is typically classified as acute or chronic. In this week's VJHemOnc podcast, we'll be sharing key highlights from the 50th Annual Meeting of the EBMT, drawing focus on the biology and treatment of GvHD.
Tune in as experts Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, Ernst Holler, MD, University Hospital Regensburg, Regensburg, Germany, and Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, provide insights into current and emerging treatment approaches for acute and chronic GvHD, discussing the advent of n...
2024-04-2622 minVJHemOnc PodcastUpdates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooksThe treatment landscape of acute lymphoblastic leukemia (ALL) has transformed with the introduction of novel immunotherapeutic agents, including CAR-T cells and antibody-based therapies. Despite these advances, several challenges remain in the field. In today’s episode, you will hear the latest updates with the use of CAR-T therapy in ALL, as discussed by renowned experts during the EBMT-EHA 6th European CAR T-cell meeting.
In this podcast, André Baruchel, MD, PhD, Hospital Robert Debré AP-HP, Paris, France, Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, and Alex Rampotas, MD, University College London, London, UK, cover severa...
2024-02-2212 minVJHemOnc PodcastUpdates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooksThe treatment landscape of acute lymphoblastic leukemia (ALL) has transformed with the introduction of novel immunotherapeutic agents, including CAR-T cells and antibody-based therapies. Despite these advances, several challenges remain in the field. In today's episode, you will hear the latest updates with the use of CAR-T therapy in ALL, as discussed by renowned experts during the EBMT-EHA 6th European CAR T-cell meeting.
In this podcast, André Baruchel, MD, PhD, Hospital Robert Debré AP-HP, Paris, France, Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, and Alex Rampotas, MD, University College London, London, UK, cover several topi...
2024-02-2212 min
WolverHeme Happy HourLymphOMG: Pouring Over Lymphoma Abstracts from ASHOMG! In this extra fun holiday episode, we are joined by lymphoma experts Tycel Phillips and Aaron Goodman to review the most impactful and controversial lymphoma abstracts from ASH! Stay tuned for a lively discussion!
Abstracts Discussed!
SYMPATICO (Ibrutinib + Ven in R/R MCL):
https://ash.confex.com/ash/2023/webprogram/Paper191921.html
Nivo-AVD in elderly Hodgkin Lymphoma:
https://ash.confex.com/ash/2023/webprogram/Paper180114.html
BOVEN - Zanubrutinib + Obi + Ven in TP53 mutant MCL:
https://ash.confex.com/ash/2023/webprogram/Paper180069.html
CAR-T in CNS Lymphoma:
https://ash.confex.com/ash/2023/webprogram/Paper174883...
2023-12-291h 12
Trainee Pearls#18 Jurjen Versluis: Transplant for high-risk MDSAllogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS) improves overall survival. The authors evaluated the impact of MDS genetics on the benefit of HCT in a biological assignment (donor v no donor) study.
https://pubmed.ncbi.nlm.nih.gov/37607457/
ALSO AS VIDEO ON
https://youtu.be/JbHS_-2sJQc
CONNECT WITH US
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trainee-committee
https://twitter.com/CarmeloGurnari
2023-10-2920 minTrainee Pearls#17 Nathanial Anderson: Signatures and persistence of CAR-T cellsIn this study, Nathanial and colleagues systematically analyzed CD19
CAR-T cells of 10 children with R/R B-ALL enrolled in the CARPALL trial
via high-throughput single-cell gene expression and T cell receptor
sequencing of infusion products and serial blood and bone marrow samples up to 5 years after infusion.
Article: https://www.nature.com/articles/s41591-023-02415-3
As VIDEO on
https://youtu.be/z_aJgRHpEaI
2023-09-0523 minTrainee Pearls#16 Aina Oliver-Caldés: Academic CAR-T cells for myelomaChimeric antigen receptor (CAR) T-cell therapy is a promising option for patients with heavily treated multiple myeloma. Point-of-care manufacturing can increase the availability of these treatments
worldwide. Aina and colleagues assessed the safety and activity of
ARI0002h, a BCMA-targeted CAR T-cell therapy developed by academia, in patients with relapsed or refractory multiple myeloma.
https://pubmed.ncbi.nlm.nih.gov/37414060/
ALSO AS VIDEO ON
https://youtu.be/Ymgg22roWGU
CONNECT WITH US
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trainee-committee
https://twitter.com/CarmeloGurnari
2023-07-1417 min
The Graft#27 IndiaALL EPISODES AS VIDEO
https://youtu.be/La-723RhDIA
CONNECT WITH US
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trainee-committee
https://twitter.com/NicoGagelmann
https://twitter.com/Claire_P_Horgan
2023-06-221h 00
O-Ton OnkologieKongress-Special: EHA2023Wir berichten vom Europäischen Hämatologiekongress, EHA. In Frankfurt haben wir u.a. mit Dr. Kai Rejeski von der LMU München gesprochen über aktuelle Empfehlungen der EHA und EBMT für „Immune effector cell-associated hematotoxicity“ (ICAHT), also hämatologische Nebenwirkungen, die unter CAR-T-Zell-Therapie auftreten. Zudem gibt es aktuelle Daten zum Sechs-Jahres-Update der CLL14-Studie mit Venetoclax /Obinutuzumab bei chronischer lymphatischer Leukämie von Dr. Othman Al-Sawaf, Uniklinik Köln.
Weitere Themen der Folge: Wie das Mikrobiom die Wirksamkeit von Therapien beeinflussen kann und welche Rolle dabei eine Antibiose spielt. Zudem diskutieren wir, welche neuen Optionen für das transfusionsa...
2023-06-2122 minTrainee Pearls#15 Francesca del Bufalo: CAR-T cells for neuroblastomaImmunotherapy with chimeric antigen receptor (CAR)–expressing T cells
that target the disialoganglioside GD2 expressed on tumor cells may be a
therapeutic option for patients with high-risk neuroblastoma. In an
academic, phase 1–2 clinical trial, the investigators enrolled patients
(1 to 25 years of age) with relapsed or refractory, high-risk
neuroblastoma in order to test autologous, third-generation GD2-CAR T
cells expressing the inducible caspase 9 suicide gene (GD2-CART01).
https://www.nejm.org/doi/full/10.1056/NEJMoa2210859
ALSO AS VIDEO ON YOUTUBE
https://youtu.be/o1DVDcrrHFA
CONNECT WITH US
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trai...
2023-05-2023 minThe Graft#26 Torsten Haferlach: Hematology, diagnostics and the futureFOLLOW MLL
Twitter: @leukaemielabor
mll.com
2023-04-0455 minTrainee Pearls#12 Justin Loke: Cytogenetics and TP53 in BMT for AMLThe presence of TP53 mutations is associated with an unfavorable outcome in patients allografted for acute myeloid leukemia (AML), leading some to question the benefit of an allogeneic stem cell transplantation (allo-SCT) for this patient group, although this has not been studied in a large cohort. Article: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.34268 ALSO AS AUDIO ON
https://podcasts.apple.com/us/podcast/trainee-pearls/id1596786132
https://open.spotify.com/show/2M1PWPZGW9Bz7PL5eh103Y
CONNECT WITH US
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trainee-committee
https://twitter.com/Ca...
2022-12-0514 minThe Graft#25 Daniela Hermelin: BlooducationFOLLOW Daniela Twitter: @HermelinMD https://www.bloodcenter.org/about/news/authors/daniela-hermelin-md-a7/ https://www.blooducation.com/about-dr-hermelin ALL EPISODES AS AUDIO APPLE https://podcasts.apple.com/de/podcast/the-graft/id1543609846 SPOTIFY https://open.spotify.com/show/2x2ovFm0cG0NmgyItygbab GOOGLE https://podcasts.google.com/feed/aHR0cHM6Ly9hbmNob3IuZm0vcy80Mjk1MzA1Yy9wb2RjYXN0L3Jzcw== CONNECT WITH US https://twitter.com/TheEBMT_Trainee https://www.ebmt.org/trainee-committee https://twitter.com/NicoGagelmann https://twitter.com/Claire_P_Horgan
2022-11-2650 minThe Graft#24 Abdul Muqtadir Abbasi: Pakistanhttps://twitter.com/AbbasiMuqtadir
CONNECT WITH US
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trainee-committee
https://twitter.com/NicoGagelmann
https://twitter.com/Claire_P_Horgan
2022-10-2050 min
NCBR na ChmielnejStartupy na Chmielnej | Marcin Bielówka z INNOventure: polski rynek VC z ciągu ostatnich 10 lat | prof. Grzegorz Basak z Saventic Health: czy choroby rzadkie uda się łatwo diagnozować dzięki AIMarcin Bielówka z branżą VC jest związany od przeszło dekady. Jest współzałożycielem i ekspert Platformy Startowej - Unicorn Hub. Obecnie pełni funkcję CEO w funduszu INNOventure, z którym zainwestował w takie spółki jak m.in.: RevDeBug.com, Saventic Health, SiDLY, Cardiomatics, AraHub, SDS Optic, PolTREG czy Laven S.A. Wcześniej CEO w Funduszu Zalążkowym KPT, z którym zainwestował m.in. w takie spółki jak: Synerise, Motivizer i EXDIN Solutions.
Jak zmienił się polski rynek VC od momentu powstania funduszu KPT do dziś?
Jak wygląda obecnie współpraca fundusz...
2022-10-0743 minTrainee Pearls#11 Ferran Nadeu: Early seeding of Richter transformationRichter transformation (RT) is a paradigmatic evolution of chronic lymphocytic leukemia (CLL) into a very aggressive large B cell lymphoma conferring a dismal prognosis. The mechanisms driving RT remain largely unknown.
Article: https://www.nature.com/articles/s41591-022-01927-8
ALSO AS AUDIO ON
https://podcasts.apple.com/us/podcast/trainee-pearls/id1596786132
https://open.spotify.com/show/2M1PWPZGW9Bz7PL5eh103Y
CONNECT WITH US
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trainee-committee
https://twitter.com/CarmeloGurnari
2022-09-2225 minTrainee Pearls#10 Elsa Bernard: IPSS-M in MDSRisk stratification and therapeutic decision-making for myelodysplastic syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS-R), which considers hematologic parameters and cytogenetic abnormalities. Somatic gene mutations are not yet used in the risk stratification of patients with MDS. Combining genomic profiling with hematologic and cytogenetic parameters, the IPSS-M improves the risk stratification of patients with MDS and represents a valuable tool for clinical decision-making.
CONNECT WITH US
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trainee-committee
https://twitter.com/CarmeloGurnari
2022-08-2328 minThe Graft#23 Jennifer Brudno: CAR-T and NIHDr. Brudno researches the use of chimeric antigen receptor (CAR) T-cell therapy to treat cancers of the blood, including Non-Hodgkin lymphoma, Hodgkin lymphoma, acute lymphoblastic leukemia (ALL), and multiple myeloma. Her focus is in the development of phase I clinical trials. She is also interested in patient safety, particularly in optimizing patient safety for cellular immunotherapies.
Nico Gagelmann and Jennifer Brudno
ALL EPISODES AS AUDIO
APPLE https://podcasts.apple.com/de/podcast/the-graft/id1543609846
SPOTIFY https://open.spotify.com/show/2x2ovFm0cG0NmgyItygbab
GOOGLE https://podcasts.google.com/feed/aHR0cHM...
2022-08-1154 minThe Graft#22 Cynthia Chmielewski: Living with myelomaCindy Chmielewski (@myelomateacher on Twitter) was diagnosed with multiple myeloma in July 2008 after suffering for two years with debilitating back pain which was wrongly attributed to degenerative disc disease.
ALL EPISODES AS AUDIO
APPLE https://podcasts.apple.com/de/podcast/the-graft/id1543609846
SPOTIFY https://open.spotify.com/show/2x2ovFm0cG0NmgyItygbab
GOOGLE https://podcasts.google.com/feed/aHR0cHM6Ly9hbmNob3IuZm0vcy80Mjk1MzA1Yy9wb2RjYXN0L3Jzcw==
CONNECT WITH US
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trainee-committee
https://twitter.com/NicoGagelmann
https://twitter.com/Claire_P_Horgan
CONNECT WITH MYELOMA ADVOCATES
https://healthtree.org...
2022-07-1946 minTrainee Pearls#9 Alice Bertaina: Stem cell-kidney transplant for SIODSchimke immuno-osseous dysplasia (SIOD) is a multisystem disorder that is inherited in an autosomal recessive pattern. It usually manifests first with growth failure. Other features of the disease are generally noted in the ensuing evaluation of the growth failure or develop in the following years.
Article: https://www.nejm.org/doi/10.1056/NEJMoa2117028?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
ALSO AS AUDIO ON
https://podcasts.apple.com/us/podcast/trainee-pearls/id1596786132
https://open.spotify.com/show/2M1PWPZGW9Bz7PL5eh103Y
YOUTUBE
2022-07-0727 min
The Graft#21 Helen Heslop: Cellular therapyHeslop is a professor of medicine and pediatrics and holds the Dan L Duncan Chair at Baylor. She is a physician-scientist engaged in translational research focusing on adoptive immunotherapy with gene-modified effector cells to improve hemopoietic stem cell transplantation and cancer therapy. She has extensive experience in developing and conducting transplant studies and cell and gene therapy studies and currently holds more than 20 Investigational New Drug Applications. She also has played a major role nationally as president of societies focusing on the intellectual and clinical development of cellular therapies and accreditation of facilities delivering cell therapies. Dr. Helen Heslop has been e...
2022-06-2736 min
Trainee Pearls#8 Marie Passet: Novel high-risk B-cell ALLOncogenic alterations underlying B-cell acute lymphoblastic leukemia (B-ALL) in adults remain incompletely elucidated. To uncover novel oncogenic drivers, Marie and her team performed RNA-seq and whole-genome analyses in a large cohort of unresolved B-ALL. Marie and colleagues identified a novel subtype characterized by a distinct gene expression signature and the unique association of two genomic microdeletions. Article link: https://ashpublications.org/blood/article/doi/10.1182/blood.2021014723/484449/Concurrent-CDX2-cis-deregulation-and-UBTF-ATXN7L3
2022-06-0825 minVJHemOnc PodcastImpact of the COVID-19 pandemic on the EBMT & projects in the pipelineThe 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), which took place on 19-23 March 2022, was held virtually for the third time in a row due to the unprecedented humanitarian crisis in Ukraine. Despite the great success of this year’s Annual Meeting, the EBMT had to face significant challenges during these past two years of COVID-19 pandemic.
Join us for this insightful discussion where leading experts Christian Chabannon, MD, PhD, Paoli-Calmettes Institute, Marseille, France, and President of the EBMT Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Ba...
2022-06-0336 minVJHemOnc PodcastImpact of the COVID-19 pandemic on the EBMT & projects in the pipelineThe 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), which took place on 19-23 March 2022, was held virtually for the third time in a row due to the unprecedented humanitarian crisis in Ukraine. Despite the great success of this year’s Annual Meeting, the EBMT had to face significant challenges during these past two years of COVID-19 pandemic.
Join us for this insightful discussion where leading experts Christian Chabannon, MD, PhD, Paoli-Calmettes Institute, Marseille, France, and President of the EBMT Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Bar...
2022-06-0336 minThe Graft#20 Ghulam Mohyuddin: Training and myelomaDr. Mohyuddin completed his medical training at Aga Khan University in Pakistan and his internal medicine residency at the University of Kansas where he developed a passion for medical education and treating hematological malignancies. He completed his fellowship developing a clinical and research interest in multiple myeloma, drug repurposing, quality of scientific methods end of life, cost-effective/evidence based care and medical education. He enjoys the outdoors, and that drew him to life in Utah where he is currently Assistant Professor at the Huntsman Cancer Institute with a focus on multiple myeloma.
2022-05-251h 07The Graft#19 Nikita Mehra: India and molecular oncologyNikita Mehra (@DrNikitaMehra) is an Associate Professor at Medical Oncology and Researcher in Molecular Oncology in the Cancer Institute (WIA), Chennai, India.
2022-05-1345 minThe Graft#18 Raffaella Greco: Autoimmune diseaseDr. Raffaella Greco (@RaffaellaGrecoM) is a hematologist in the Department of Hematology and Bone Marrow Transplantation at the IRCCS Ospedale San Raffaele under the supervision of Professor Fabio Ciceri. After graduating in 2008 from the Faculty of Medicine and Surgery of the University of Milan Vita-Salute San Raffaele received a specialization in hematology at the same university in 2014.
CONNECT WITH US
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trainee-committee
https://twitter.com/NicoGagelmann
https://twitter.com/Claire_P_Horgan
2022-05-0445 minTrainee Pearls#7 Rafal Machowicz: Transplant for HLHHemophagocytic lymphohistiocytosis (HLH; hemophagocytic syndrome) is a rare syndrome of potentially fatal, uncontrolled hyperinflammation. Allogeneic hematopoietic stem cell transplantation is indicated in primary, recurrent or progressive HLH, but information about its outcomes in the adult population is limited.
Rafal works at the Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland. And he is part of YoungEHA.
2022-04-2836 minThe Graft#17 Nihar Desai: IndiaFinal year hematology fellow: @nihardesai7
Interview: Nico Gagelmann, Claire Horgan
CONNECT WITH US
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trainee-committee
https://twitter.com/NicoGagelmann
https://twitter.com/Claire_P_Horgan
2022-04-241h 01
AML HubHow are new fludarabine conditioning combinations impacting transplant outcomes?During the virtual 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke with Eleni Gavriilaki, George Papanikolaou General Hospital of Thessaloniki, Thessaloniki, GR. We asked, How are new fludarabine conditioning combinations impacting transplant outcomes?Gavriilaki begins by discussing a study presented at EBMT 2022 that explored outcomes of fludarabine + treosulfan, which followed on from previous studies exploring treosulfan. Gavriilaki details the study design and patient population, explaining which comparative therapies were used and why. Finally, Gavriilaki outlines different studies presented at EBMT covering fludarabine combinations for patients with AML...
2022-04-2206 min
The Health Design PodcastCindy Chmielewski, Patient AdvocateCynthia lives in Lawrenceville, NJ with her husband John. She attended Rutgers University graduating with degrees in Psychology and Education. Upon graduation she secured her first teaching position and immediately fell in love with her chosen profession. Cynthia continued teaching for 28 years.
Cynthia, a myeloma survivor, was forced to retire from her beloved teaching career when a stem cell transplant failed to put her cancer into remission. Now retire, she is using her passion for education to teach a new group of "students" - myeloma patients and their caregivers. Using social media to educate is her passion. Cynthia educates and...
2022-04-1130 min2022-03-1653 minTrainee Pearls#6 Madelon de Jong: Myeloma & tumor microenvironmentProgression and persistence of malignancies are influenced by the local tumor microenvironment, and future eradication of currently incurable tumors will, in part, hinge on our understanding of malignant cell biology in the context of their nourishing surroundings. Article: https://www.nature.com/articles/s41590-021-00931-3
CONNECT with Trainee Committee https://twitter.com/TheEBMT_Trainee https://www.ebmt.org/trainee-committee
CONNECT with Madelon https://twitter.com/maadulon
MORE about EBMT https://www.ebmt.org/ https://twitter.com/TheEBMT
2022-03-1025 minThe Graft#15 Arina Martynchyk: Ukrainehttps://www.uicc.org/membership/national-cancer-institute-kiev-ukraine
2022-03-0635 minThe Graft#14 Sanam Loghavi: HematopathologyAssistant Professor, Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Interview: Nico Gagelmann, Claire Horgan
2022-02-1333 minTrainee Pearls#5 Oscar Brück: Machine learning in histopathologyHistopathology is elementary in the diagnostics of patients with MDS, but its high-dimensional data are underused. By elucidating the association of morphologic features with clinical variables and molecular genetics, this study highlights the vast potential of convolutional neural networks in understanding MDS pathology and how genetics is reflected in BM morphology. Article: https://bloodcancerdiscov.aacrjournals.org/content/2/3/238
2022-02-0432 minThe Graft#13 Toby Eyre: CLL - past, present, futureDr Toby Eyre is a substantive consultant haematologist at Oxford University Hospitals NHS Foundation Trust specialising in the management of lymphoid malignancies. He is considered a national expert in the management of patients with lymphoma and patients with chronic lymphocytic leukaemia. Twitter: https://twitter.com/TobyEyre82 Interview: Nico Gagelmann
2022-01-2853 minTrainee Pearls#4 Christopher Gibson: Clonal Hematopoiesis and transplantationClonal hematopoiesis (CH) is an age-related, asymptomatic condition in which leukemia-associated somatic mutations are detected in the blood of individuals without a hematologic malignancy. In the nontransplant setting, CH is uniformly associated with adverse outcomes, including an elevated risk of developing hematologic malignancies and an increased risk of nonhematologic outcomes because of altered inflammatory signaling. Current evidence has thus been insufficient to resolve disagreement about whether to screen older candidate donors for CH, and some transplant centers have begun excluding donors found to have CH on the basis of the assumption that the adverse associations of native CH also apply in th...
2022-01-2140 minTrainee Pearls#3 Francesca Tucci: Hurler Syndrome and gene therapyHurler syndrome, also known as mucopolysaccharidosis Type IH (MPS-IH), Hurler's disease, and formerly gargoylism, is a genetic disorder that results in the buildup of large sugar molecules called glycosaminoglycans (GAGs) in lysosomes. The inability to break down these molecules results in a wide variety of symptoms caused by damage to several different organ systems, including but not limited to the nervous system, skeletal system, eyes, and heart. Allogeneic hematopoietic stem-cell transplantation is the standard of care for Hurler syndrome (mucopolysaccharidosis type I, Hurler variant [MPSIH]). However, this treatment is only partially curative and is associated with complications.
Join our conver...
2022-01-0828 minThe Graft#12 Ruemu Birhiray: Access and diversity in medicine and research, ASHDr. Birhiray earned a Doctor of Medicine degree from the University of Benin, Nigeria, and completed his Internal Medicine residency at Columbus Hospital (an affiliate of Northwestern University) in Chicago, Illinois. He completed fellowships in Bone Marrow Transplant and Medical Oncology at Johns Hopkins University and The National Cancer Institute in Bethesda, Maryland, respectively. Dr. Birhiray has participated in research and is published on the subjects of immunotherapy, lymphomas and bone marrow transplantation. Dr. Birhiray is a member of The American Society of Clinical Oncology, American Society of Hematology, American Medical Association and the Wisconsin Medical Society. Interview: Nico Gagelmann...
2021-12-1939 minTrainee Pearls#2 Emma Groarke: VEXAS syndromeVEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently described autoinflammatory syndrome characterized by diffuse inflammatory manifestations, predisposition to hematological malignancy, and an association with a high rate of thrombosis. VEXAS is attributed to somatic mutations in the UBA1 gene in hematopoietic stem and progenitor cells with myeloid restriction in mature forms.
Join our conversation with Emma Groarke from the National Cancer Institute, USA, to understand how it was discovered and more.
Article: https://www.nejm.org/doi/10.1056/NEJMoa2026834?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0p...
2021-12-0530 minThe Graft#11 Trainee realities in Latin AmericaThe following podcast hosts trainees from Latina America, Laura Saavedra from Venezuela, Andres Gomez from Mexico, Rafaela Muratori from Brazil and Susy Bazan from Peru. This recording is the second part, where we discuss shared experiences and challenges. But most of the time, we will listen to them and learn from them. The first part with presentations of each country can be found on our youtube channel: https://youtu.be/fJmv5glG1sY
2021-12-031h 11Trainee Pearls#1 Sushree Sahoo: SAMD9/SAMD9L syndromesClinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes. Sahoo SS, et al. Nat Med. 2021 Oct;27(10):1806-1817. doi: 10.1038/s41591-021-01511-6
2021-11-2226 min
The MS Trust podcastHSCT for MSSend us a message about the podcast. For questions about MS please contact our helpline 0800 032 38 39We discuss the 'hot topic' of HSCT for MS, hearing from Claire in the Information team about the criteria for receiving stem cell transplantation. Our guests also include Chris who was eligible for HSCT on the NHS and Gwen who went to Russia to seek treatment for PPMS. Both share their experiences of HSCT and give advice for anyone else considering the option.Episode notes:- MS Trust A-Z page - Stem cells and MS...
2021-11-181h 29The Graft#10 Nada Hamad: Access and diversity in training and healthcare, ANZTCTThe following is a conversation with Prof Nada Hamad, a senior staff specialist in bone marrow transplant, clinical and laboratory haematologist at St Vincent’s hospital in Sydney, where she is also director of the haematology clinical trials unit. She is President of the Bone Marrow Transplant Society of Australia and New Zealand. She is a senior lecturer at the University of Sydney and University of NSW.
2021-11-1857 minThe Graft#9 Vincent Rajkumar: myeloma, COVID, drug costs, mistakes, trainingThe following is a conversation with Prof Vincent Rajkumar is engaged in clinical, epidemiological and laboratory research in myeloma and related disorders. Dr. Rajkumar served as the principal investigator on several clinical trials for the treatment of myeloma. We talk with him about myeloma, COVID, how he thinks trainees can make sense of all the data out there, access to treatments and drug costs.
Interview: Nico Gagelmann, Claire Horgan
2021-10-101h 06
The New Horizon TalksEpisode 2: Transforming the Future of Healthcare TogetherIn this episode, we look at the unique policy challenges presented by cell and gene therapies from research & development through to patient access; and the role of multi-stakeholder collaborations, in particular those active in supporting European policymaking. How can we, together, deliver these innovative therapies to patients and society, efficiently and safely?
Guests:
• Amanda Bok, Chief Executive, European Haemophilia Consortium (EHC)
• Alexander Natz, CEO, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
----
Abbreviations:
• ATMPs: Advanced therapy medicinal products
• EBMT: European Society for Blood and Marrow Transplantation
• G...
2021-09-2728 minThe Graft#8 Chris Lewis: cancer, discrimination, COVID, death, communicationThis conversation is about cancer and all the overwhelming challenges and potential discrimination that come with the diagnosis, inequalities, death, the impact of COVID, the importance of time and communication, and Chris' unique and inspiring story.
His website: www.chris-cancercommunity.com
SimPal: https://www.yoursimpal.com/
Interview: Nico Gagelmann
2021-08-051h 18The Graft#7 Chadi Nabhan: good medicine, death, shame, science, public healthThe following is a conversation with Chadi Nabhan, Chairman of Precision Oncology Alliance at Caris Life Sciences. We talk with him about good medicine, the art of being human, actually caring for patients, and the essence of science and its abuse in current times of COVID. With his podcast "healthcare unfiltered", his perspective articles in Journal of Clinical Oncology, JAMA and others, he is a really human voice in an ever challenging environment of pretenders.
Previously, Dr. Nabhan was an Associate Professor of Medicine, and Medical Director of the Clinical Cancer Center at the University of Chicago...
2021-07-121h 04The Graft#6 Aaron Goodman: Good education, communication, and twitterThe following is a conversation with Dr Aaron Goodman, hematologist/oncologist at the University of California San Diego. What is good medical education? How do we best learn to communicate? What does twitter mean for medical science?
Interview: Nico Gagelmann, Claire Horgan
2021-06-1653 minThe Graft#5 Robert Panza: being a stem cell courier, donation, COVIDThe following is a conversation with Robert Panza, former policeman from California and volunteer stem cell courier for the National Marrow Donor Program in the United States. We talk about the National Marrow Donor Program, how Robert got into being a stem cell courier, what it means, funny and sad stories, challenges and wonders since the pandemic.
Interview: Nico Gagelmann (https://twitter.com/NicoGagelmann)
MORE about our Trainee Committee on
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trainee-committee
MORE about EBMT on
https://www.ebmt.org/ http...
2021-05-151h 24The Graft#4 Bronwen Shaw: World Marrow Donor AssociationBronwen Shaw is MD and Professor at the Froedtert and the Medical College of Wisconsin and the current president of the World Marrow Donor Association (WMDA), which is made up of organisations and individuals who promote global collaboration and best practices for the benefit of stem cell donors and transplant patients. WMDA was informally initiated in 1988 by three pioneers in the field of transplantation: John Goldman (United Kingdom), E. Donnall Thomas (United States) and Jon J. van Rood (the Netherlands). This led to the foundation of WMDA in 1994. In 2007, WMDA became one of the founding members of the Worldwide Network f...
2021-04-2024 min
BP NewscastBP Newscast | Episódio 7Recomendação aos pacientes: acessar exames da BP Medicina Diagnóstica via internet | Atualizações da Nota Técnica BP | Dr. Antonio Buzaid esclarece dúvidas sobre imunização em pacientes oncológicos | Dr. Mauricio Abrão assume Vice-Presidência da AAGL | LGPD | BP no EBMT 2021 | Encontro Médico Virtual 2021 | BP Reconecta: Vanessa Karam, psicóloga da BP, fala sobre insônia
Áudio editado por Nothing Matters Produções | Instagram: @nothingmatters.prod
2021-03-3008 minThe Graft#3 Stanley Riddell: past, present, and future of CAR T cell therapyProf Stanley Riddell is a world leader in developing immunotherapies using adoptive T cell therapy.
Fasten your seatbelt and enjoy this rush from basic research to clinical reasoning.
2021-02-0359 minThe Graft#2 Clip: What happens with my manuscript after submission?Dr. Lan-Lan Smith on the process after a manuscript got submitted.
2021-01-1915 minThe Graft#2 Lan-Lan Smith: science, publication, review process, and The Lancet journalsDr. Lan-Lan Smith is founding editor of The Lancet Haematology and former senior editor of The Lancet Oncology.
This conversation is about science, its communication and publication, scientific review process, and The Lancet journal family.
2021-01-1959 minThe Graft#1 Clips: Important milestones of stem cell transplantationGösta Gahrton on important milestones of stem cell transplantation and cellular therapy.
2020-12-0822 min2020-12-0822 minThe Graft#1 Clips: 1st transplant and the luck of treating a wrestlerGösta Gahrton on the history of stem cell transplantation and his first experiences.
2020-12-0811 min2020-12-0835 minThe Graft#1 Gösta Gahrton: Nobel Prize, history of stem cell transplantation and EBMTGösta Gahrton is Professor of Medicine at Department of Medicine, Huddinge, Karolinska Institute, Sweden. He was Head of Hematology at Huddinge Hospital and Head of the Department of Medicine Karolinska Institutet, where he established one of the first bone marrow transplantation centers. Prof Gahrton has been a member and chairman of the Nobel Committee of the Karolinska Institutet.
2020-12-062h 19
Product Owner Perspective#3 The future of Scrum.org, Scrum Studio & EBMT – Dave West (Scrum.org)In this podcast I had the pleasure to chat with Dave West, Product Owner & CEO for scrum.org. After discussing his road towards becoming a Product Owner (which includes a well known three letter acronym), we go in to the three most important things a Product Owner should master. Along the ride we gain insights […]
2017-03-301h 05
Journal of Clinical Oncology (JCO) Podcast"Anything You Can't Do, I Can't Do Either": Transplantation for High Risk AMLThis is a commentary on a report from the EBMT demonstrating a higher relapse rate after allogeneic transplantation in AML patients with FLT3 ITD mutations.
2012-01-3010 min
Medizinische Fakultät - Digitale Hochschulschriften der LMU - Teil 12/19Europäische Multicenter-Analyse über die Entstehung von Sekundärmalignomen nach hämatopoetischer Stammzelltransplantation bei LangzeitüberlebendenHintergrund: Patienten nach HSZT haben ein ansteigendes Risiko erneut an malignen Zweittumoren zu erkranken. Die Häufigkeit und Risikofaktoren für maligne Zeittumore bei Langzeitüberlebenden wurden in dieser retrospektiven
Multicenter-follow-up-Studie berechnet. In der bereits 1999 vorgenommenen Analyse dieser 1036 Patienten aus 45 Transplantationszentren der EBMT, welche mehr als 5 Jahre nach Transplantation überlebten, galten Patientenalter und
Immunsuppression als Hauptrisikofaktoren für die Entstehung von malignen Zweittumoren.
Patienten und Methoden: In der aktuellen Follow-up Studie konnten Daten von 636 Patienten erneut erhoben werden, 100 Patienten starben und von 300 Patienten konnten die Daten nicht aktualisiert werden. Erneut wurden Zweittumore erfragt, die kumulative Inzidenz ermittelt und einer Vergleichsgruppe nach...
2010-12-0200 min